Home / Guides / Pipeline

Pipeline guides.

Deep dives on the next generation of obesity drugs — what's in clinical trials, when they might be available, and what they mean for patients.

Pipeline · 7 min read
Survodutide: The Dual Glucagon/GLP-1 Agonist Coming for Liver Disease and Obesity
Boehringer Ingelheim's survodutide takes a different approach — activating glucagon alongside GLP-1. The result is strong weight loss plus a unique effect on liver fat that could make it the first drug to treat MASH. Here's where it stands.
Apr 2026
Pipeline · 7 min read
MariTide (Amgen): The Monthly GLP-1 Injection Coming in 2027?
Amgen's MariTide is a once-monthly GLP-1/GIP antibody-peptide conjugate in Phase 3 trials. How it works, early results, and what it means for the GLP-1 market.
Apr 2026
Pipeline · 5 min read
Orforglipron: The Oral GLP-1 That Could Change Pricing
A non-peptide pill, 15% weight loss, and potentially much cheaper to manufacture. Why Lilly's orforglipron could restructure the GLP-1 market.
Apr 2026
Pipeline · 6 min read
Retatrutide: What We Know About Lilly's Next-Gen GLP-1
24% weight loss in Phase 2, three-hormone mechanism, and on track for FDA filing in 2026-2027. Here's what retatrutide actually is and why it matters.
Apr 2026